China's new crown vaccine has been triald in the United Arab Emirates, Brazil.

(2020/07/22) Kangmei Pharmaceuticals: 21 people were disciplined and fined multiple jobs; 29 pharmaceutical companies panoramic report card published; Health Insurance Bureau: supplies negotiations to reduce prices related to Johnson and Johnson, minimally invasive, Stryker, Xerox ... (Click on the title, get the original text) (Pharmaceutical Time 1) For type 2 diabetes sotagliflozin 4 clinical endpoint of Phase III Lexicon Corporation has announced the SGLT 1/2 inhibitor sotagliflozin for type 2 diabetes 4 Phase III clinical studies of the top line data: 4 studies have reached the main endpoint to reduce blood sugar levels in patients with T2D.
: Both doses significantly reduced A1C.
: China's new crown vaccine launched trials in the United Arab Emirates, Brazil, the world's first vaccine as soon as September 21st, Brazil began a Phase III clinical trial of the new crown vaccine developed by Chinese pharmaceutical company Kexing, the first batch of about 900 volunteers participated.
the same test will be launched in Bangladesh. On June 23,
, China Biologicals, a Chinese pharmaceutical group, announced that its Phase III clinical trial sat trial had been launched in the United Arab Emirates.
headlines: The new crown vaccine is sure to appear this year.
"Seiber blue equipment" health insurance bureau: supplies negotiations to reduce prices related to Johnson and Johnson, minimally invasive, Stryker, Xerox... On the 20th, Jiangsu Province Medical Insurance Bureau issued the "third round of medical supplies in the province medical supplies group alliance centralized procurement announcement (II)," the Medical Insurance Bureau pointed out that the medical supplies group alliance centralized procurement will adhere to the principle of quality first.
headlines: 70% of the total annual purchase.
,E Pharmaceutical Managers' Annual Report book of 29 pharmaceutical companies, the panoramic report card was announced a year ago, as the two pharmaceutical biological enterprises represented by Southern Micromedicine and Cardiology Medicine, as one of the first 25 science and technology board listed enterprises, successfully opened the door to the capital market.
and a year later today, focusing on antibody drug research and development of innovative biological drug enterprises, Sansheng Guojian successfully landed on the company's board listing, becoming the 29th in 2020 to the company's first branch board enterprises, but also since the opening of the board, the 29th listed biopharmaceutical companies.
today Sansheng Guojian opened 44 yuan / share, as of the time of writing the highest 57.3 yuan / share, the total market value of more than 30 billion yuan.
headlines: The future of the Cotron board.
: 21 people were disciplined and the number of people banned from the industry on the 21st, the Shanghai Stock Exchange issued a decision on the disciplinary action against Kangmei Pharmaceutical Co., Ltd., the actual controller and then chairman and general manager Ma Xingtian and the relevant responsible person, publicly found Ma Xingtian and other senior executives not suitable for life as directors, supervisors and senior managers of listed companies.
headlines: Industry bans.
.